Australian and New Zealand Intensive Care Research Centre (ANZIC-RC)

We drive the development, conduct and translation of pivotal, large scale research projects in critical care, and build research capacity in the field. Our work has revolutionised practice globally, saving countless lives, improving outcomes and reducing health expenditure.

We're part of the School of Public Health and Preventive Medicine.

  • Over $40M in competitive funding since 2020

  • 20,000 patients recruited to our trials

  • Worldwide collaboration

  • Unparalleled opportunities to conduct research in critical care

News

New REMAP-CAP trial results: Oseltamivir in critically ill patients with influenza infection

New results from the REMAP-CAP trial have found that oseltamivir – long considered a standard treatment for influenza (flu) – appears to increase the risk of death in patients who are critically ill in an intensive care unit (ICU). Australian ICUs have been asked to pause its use in critically ill patients while these initial results are reviewed.

Read the Explainer

Our news highlights

View more articles